Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Total Non-Current Liabilities of $185.2 million for Q1 2026, up 8.74% YoY from $170.3 million in Q1 2025, and down 7.63% sequentially from $200.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $185.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 8.74% year-over-year to $185.2 million; the TTM figure through Mar 2026 stood at $185.2 million (up 8.74% YoY), while the FY2025 annual figure was $200.5 million, up 6.86% from the prior year.
- Total Non-Current Liabilities declined to $185.2 million in Q1 2026, from $200.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for AMRN reached as high as $385.6 million in Q2 2022 and fell as low as $170.3 million in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $238.6 million (2024), against an average of $247.8 million.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 30.63% — and 2026, when it gained 8.74%.
- A 5-year view of Total Non-Current Liabilities shows it stood at $282.6 million in 2022, then retreated by 4.29% to $270.5 million in 2023, then tumbled by 30.63% to $187.7 million in 2024, then climbed by 6.86% to $200.5 million in 2025, then dropped by 7.63% to $185.2 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $185.2 million, $200.5 million, and $189.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 185.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 185.23 Mn |
| Dec 31, 2025 | 200.54 Mn |
| Sep 30, 2025 | 188.96 Mn |
| Jun 30, 2025 | 193.28 Mn |
| Mar 31, 2025 | 170.35 Mn |
| Dec 31, 2024 | 187.67 Mn |
| Sep 30, 2024 | 209.77 Mn |
| Jun 30, 2024 | 238.64 Mn |
| Mar 31, 2024 | 234.88 Mn |
| Dec 31, 2023 | 270.52 Mn |
| Sep 30, 2023 | 278.61 Mn |
| Jun 30, 2023 | 283.74 Mn |
| Mar 31, 2023 | 266.79 Mn |
| Dec 31, 2022 | 282.64 Mn |
| Sep 30, 2022 | 310.78 Mn |
| Jun 30, 2022 | 385.56 Mn |
| Mar 31, 2022 | 325.11 Mn |
| Dec 31, 2021 | 393.32 Mn |
| Sep 30, 2021 | 387.96 Mn |
| Jun 30, 2021 | 394.14 Mn |